Zealand Pharma's restructuring plan has led to dismissals in Denmark

Last week’s announcement that Zealand Pharma was planning to scale down its operations in the US by 90 percent has had a wider impact than first assumed – CEO Adam Steensberg now tells MedWatch that Danish staffing has also been reduced.
Adam Steensberg, CEO of Zealand Pharma | Photo: Zealand Pharma
Adam Steensberg, CEO of Zealand Pharma | Photo: Zealand Pharma
by christopher due karlsson, translated by daniel pedersen

More than just Zealand Pharma’s employees in the US are bearing the brunt of the company’s streamlining plans. Danish staffing has also suffered a blow, says the newly appointed CEO, Adam Steensberg, to MedWatch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading